Nature Communications (Oct 2022)
The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma
- Jens Bauer,
- Natalie Köhler,
- Yacine Maringer,
- Philip Bucher,
- Tatjana Bilich,
- Melissa Zwick,
- Severin Dicks,
- Annika Nelde,
- Marissa Dubbelaar,
- Jonas Scheid,
- Marcel Wacker,
- Jonas S. Heitmann,
- Sarah Schroeder,
- Jonas Rieth,
- Monika Denk,
- Marion Richter,
- Reinhild Klein,
- Irina Bonzheim,
- Julia Luibrand,
- Ursula Holzer,
- Martin Ebinger,
- Ines B. Brecht,
- Michael Bitzer,
- Melanie Boerries,
- Judith Feucht,
- Helmut R. Salih,
- Hans-Georg Rammensee,
- Stephan Hailfinger,
- Juliane S. Walz
Affiliations
- Jens Bauer
- Department of Peptide-based Immunotherapy, University and University Hospital Tübingen
- Natalie Köhler
- Department of Internal Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, Albert Ludwigs University
- Yacine Maringer
- Department of Peptide-based Immunotherapy, University and University Hospital Tübingen
- Philip Bucher
- Cluster of Excellence iFIT (EXC2180) “Image-Guided and Functionally Instructed Tumor Therapies”, University of Tübingen
- Tatjana Bilich
- Department of Peptide-based Immunotherapy, University and University Hospital Tübingen
- Melissa Zwick
- Department of Internal Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, Albert Ludwigs University
- Severin Dicks
- Faculty of Biology, Albert-Ludwigs-Universität
- Annika Nelde
- Department of Peptide-based Immunotherapy, University and University Hospital Tübingen
- Marissa Dubbelaar
- Department of Peptide-based Immunotherapy, University and University Hospital Tübingen
- Jonas Scheid
- Department of Peptide-based Immunotherapy, University and University Hospital Tübingen
- Marcel Wacker
- Department of Peptide-based Immunotherapy, University and University Hospital Tübingen
- Jonas S. Heitmann
- Cluster of Excellence iFIT (EXC2180) “Image-Guided and Functionally Instructed Tumor Therapies”, University of Tübingen
- Sarah Schroeder
- Department of Peptide-based Immunotherapy, University and University Hospital Tübingen
- Jonas Rieth
- Department of Peptide-based Immunotherapy, University and University Hospital Tübingen
- Monika Denk
- Department of Peptide-based Immunotherapy, University and University Hospital Tübingen
- Marion Richter
- Department of Peptide-based Immunotherapy, University and University Hospital Tübingen
- Reinhild Klein
- Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen
- Irina Bonzheim
- Department of Pathology and Neuropathology, University Hospital Tübingen
- Julia Luibrand
- Department of Pathology and Neuropathology, University Hospital Tübingen
- Ursula Holzer
- Department of Pediatric Hematology and Oncology, University Children’s Hospital, University of Tübingen
- Martin Ebinger
- Department of Pediatric Hematology and Oncology, University Children’s Hospital, University of Tübingen
- Ines B. Brecht
- Department of Pediatric Hematology and Oncology, University Children’s Hospital, University of Tübingen
- Michael Bitzer
- Cluster of Excellence iFIT (EXC2180) “Image-Guided and Functionally Instructed Tumor Therapies”, University of Tübingen
- Melanie Boerries
- Institute of Medical Bioinformatics and Systems Medicine, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg
- Judith Feucht
- Cluster of Excellence iFIT (EXC2180) “Image-Guided and Functionally Instructed Tumor Therapies”, University of Tübingen
- Helmut R. Salih
- Cluster of Excellence iFIT (EXC2180) “Image-Guided and Functionally Instructed Tumor Therapies”, University of Tübingen
- Hans-Georg Rammensee
- Department of Immunology, Institute for Cell Biology, University of Tübingen
- Stephan Hailfinger
- Cluster of Excellence iFIT (EXC2180) “Image-Guided and Functionally Instructed Tumor Therapies”, University of Tübingen
- Juliane S. Walz
- Department of Peptide-based Immunotherapy, University and University Hospital Tübingen
- DOI
- https://doi.org/10.1038/s41467-022-33746-3
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 16
Abstract
The DNAJB1-PRKACA fusion transcript is the oncogenic driver in fibrolamellar hepatocellular carcinoma, a lethal disease with limited therapeutic options. Here, the authors identify the DNAJB1-PRKACA protein as a source for immunogenic neoepitopes and a potential target of T cell-based immunotherapy.
